Zenas BioPharma (NASDAQ:ZBIO) Trading Down 6.1% – Time to Sell?

Zenas BioPharma, Inc. (NASDAQ:ZBIO)’s share price fell 6.1% during trading on Monday . The stock traded as low as $18.68 and last traded at $18.5950. 284,498 shares were traded during trading, a decline of 65% from the average session volume of 808,482 shares. The stock had previously closed at $19.80.

Analysts Set New Price Targets

Several research firms have recently commented on ZBIO. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Guggenheim lifted their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Morgan Stanley lifted their price objective on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $44.29.

Zenas BioPharma Price Performance

The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The firm’s 50 day moving average is $19.25 and its 200-day moving average is $24.12.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same quarter last year, the business posted ($0.80) earnings per share. Equities analysts forecast that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Insider Activity at Zenas BioPharma

In other Zenas BioPharma news, Director Hongbo Lu acquired 3,768 shares of Zenas BioPharma stock in a transaction that occurred on Tuesday, March 31st. The stock was acquired at an average price of $18.63 per share, with a total value of $70,197.84. Following the purchase, the director owned 426,736 shares in the company, valued at approximately $7,950,091.68. This trade represents a 0.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Leon O. Moulder, Jr. acquired 60,000 shares of Zenas BioPharma stock in a transaction that occurred on Monday, May 18th. The stock was acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the purchase, the chief executive officer owned 96,928 shares in the company, valued at $1,636,144.64. The trade was a 162.48% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 273,768 shares of company stock valued at $5,150,198. Insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Quarry LP lifted its position in Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Zenas BioPharma during the 3rd quarter worth $30,000. GF Fund Management CO. LTD. acquired a new position in Zenas BioPharma during the 4th quarter worth $38,000. BNP Paribas Financial Markets lifted its position in Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after acquiring an additional 1,716 shares during the last quarter. Finally, CWM LLC lifted its position in Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after acquiring an additional 709 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.